收藏切换
Progress in targeted protein degradation for central nervous system diseases therapy
收藏切换
Xue ZHANG1, Ya-xuan FENG1, Liu ZHANG1, Lu SUN1, *, Hui-ning HE1, 2, *
Acta Pharmaceutica Sinica | 2025, 60(11) : 3318 - 3329
Less
收藏切换
Acta Pharmaceutica Sinica | 2025, 60(11): 3318-3329
• Special Reports: Recent advances in targeted protein degradation therapeutics •
Progress in targeted protein degradation for central nervous system diseases therapy
Full
Xue ZHANG1, Ya-xuan FENG1, Liu ZHANG1, Lu SUN1, *, Hui-ning HE1, 2, *
Affiliations
  • 1Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China
  • 2School of Biomedical Engineering and Technology, Tianjin Medical University, Tianjin 300070, China
Published: 2025-11-12 doi: 10.16438/j.0513-4870.2025-0804
Outline
收藏切换

The development of therapeutic interventions for central nervous system (CNS) diseases poses significant challenges. These challenges are primarily attributable to the limitations imposed by the blood-brain barrier (BBB) permeability and the inherent complexity of protein aggregates. Targeted protein degradation (TPD) technology selectively removes pathogenic proteins through the ubiquitin-proteasome system or lysosomal pathways, offering a new strategy for CNS treatment. In comparison with conventional small molecule drugs, TPD employs an event-driven mode of action, capable of degrading β-amyloid and other "undruggable" targets, and demonstrating efficacy at sub-chemometric doses. This is anticipated to markedly reduce the complexity of CNS delivery. The disconnecting of pharmacodynamics and pharmacokinetics further reduces the risk of off-targeting, making it particularly suitable for the CNS, a therapeutic area that requires a high degree of drug safety. Three CNS degraders have already entered clinical trials. This review comprehensively elaborates on the application progress of TPD technologies based on different degradation systems in the treatment of CNS diseases, systematically analyzes the advantages and limitations of each technology, and discusses the common challenges and general optimization strategies for TPD application in CNS disease therapy. The findings aim to provide new insights for the in-depth application of TPD technology in the treatment of CNS diseases.

central nervous system disease  /  targeted protein degradation  /  degrader  /  ubiquitin-proteasome system  /  lysosomal degradation pathway
张雪, 冯雅煊, 张柳, 孙璐, 贺慧宁. 靶向蛋白降解技术在中枢神经系统疾病治疗中的应用进展. 药学学报, 2025 , 60 (11) : 3318 -3329 . DOI: 10.16438/j.0513-4870.2025-0804
Xue ZHANG, Ya-xuan FENG, Liu ZHANG, Lu SUN, Hui-ning HE. Progress in targeted protein degradation for central nervous system diseases therapy[J]. Acta Pharmaceutica Sinica, 2025 , 60 (11) : 3318 -3329 . DOI: 10.16438/j.0513-4870.2025-0804
Year 2025 volume 60 Issue 11
369
178
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2025-0804
  • Receive Date:2025-07-11
  • Online Date:2026-09-20
  • Published:2025-11-12
Article Data
Affiliations
History
  • Received:2025-07-11
  • Revised:2025-10-09
Affiliations
    1Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China
    2School of Biomedical Engineering and Technology, Tianjin Medical University, Tianjin 300070, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2025-0804
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT